XMD-12

• Description :

  XMD-12 (compound 1) is an Aurora kinase (Aurora Kinase) inhibitor with anti-tumor activity that promotes paclitaxel (HY-B0015) induced cell death. XMD-12 exhibits high selectivity and potency against Aurora A, B, and C kinases, with IC50 values of 5.6, 18.4, and 24.6 nM, respectively[1].

• UNSPSC :

  12352005

• Target :

  Aurora Kinase

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Purity :

  99.32

• Solubility :

  DMSO : 100 mg/mL (ultrasonic)

• Smiles :

  O=C1C2=CC=CC=C2N(C)C3=NC(NC4=CC=C(N5CCC(O)CC5)C=C4)=NC=C3N1C

• Molecular Formula :

  C24H26N6O2

• Molecular Weight :

  430.50

• References & Citations :

  [1]Nicholas Kwiatkowski, et al. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen. ACS Chem Biol. 2012 Jan 20;7 (1) :185-96.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Aurora A; Aurora B; Aurora C

• CAS Number :

  [1234481-08-3]